New Post Public Reply Private Reply Replies (0) Message Board ← Newer Older → News Desk 2018 Feb 6, 2017 at 7:45 AM 83 Immunovaccine Inc. (IMMVF: OTCQX International) | Immunovaccine's Lead Immuno-Oncology Candidate to Enter Investigator-Sponsored Phase 2 Clinical Trial in Ovarian Cancer in Combination With Approved Anti-PD-1 Drug Newer Older
